摘要
目的:评价舌下含服变应原疫苗滴剂治疗尘螨引起的变应性鼻炎(Allergic Rhinitis,AR)的疗效及安全性。方法:518例尘螨过敏为主的AR患者,其中441例愿意接受舌下含服标准化尘螨变应原疫苗滴剂治疗(sublingual immunotherapy,SLIT)为免疫治疗组,其余77例为对照组(采用对症治疗),两组患者一般状况具有可比性。所有患者治疗1年半。随访观察并记录治疗后症状得分、体征评分、药物评分及不良反应等情况。结果:免疫治疗组及对照组治疗1年半后其鼻部症状得分、体征评分、用药得分均较治疗前有显著改善,但免疫治疗组与对照组相比,其1年半后症状得分、体征评分、药物评分及疗效均明显高于对照组。同时,免疫治疗组有部分患者出现了一定程度的不良反应,但多为中等或轻微的不良反应。结论:SLIT是治疗尘螨引起的AR的一种有效治疗方法,并具有较好的安全性。但其远期疗效及不良反应情况尚需进一步临床观察。
Objective:To evaluate the efficacy and safety of sublingual immunotherapy(SLIT) treated allergicrhinitis(AR) for 1 and 1/2 years.Methods:518 patients with AR,441 cases of those who were willing to accept SLIT in immunotherapy group,the remaining 77 cases in the control group.The general situation of the two groups were comparable.All patients were treated and were followed up for 1 and 1/2 years.The symptom scores,sign scores,medication scores and adverse reactions of drugs were recorded after treatment.Results:The symptom scores,sign scores,medication scores of the 2 groups were significantly improved compared before treatment,but compared immunotherapy group and control group,the symptom scores,sign scores,medication scores and efficacy of immunotherapy group were much better than those of control group.At the same time,some local and systemic reactions were found in the immunotherapy group some extent.Conclusion:SLIT is an effective and safe method for treatment of AR.But the long-term efficacy and adverse reaction still need further clinical observation.
